FDA Classifies Germ-Fighting Gadget for Safer Labs
Published Date: 6/13/2025
Rule
Summary
The FDA is officially putting a new device called the cellular analysis system for multiplexed antimicrobial susceptibility testing into a special safety category called Class II. This means the device will have clear safety rules to follow, helping it get to patients faster and work better. Labs and companies making or using this device should get ready for these changes, which aim to keep things safe without slowing down innovation.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Device Classified as Class II
The FDA has classified the cellular analysis system for multiplexed antimicrobial susceptibility testing as Class II (special controls). The agency says this classification provides a reasonable assurance of safety and effectiveness and is intended to enhance patients' access to the device by reducing regulatory burdens.
Labs & Makers Should Prepare
Laboratories and companies that make or use the cellular analysis system for multiplexed antimicrobial susceptibility testing should get ready for new special controls that will be codified under the Class II classification. The FDA says these controls aim to keep the device safe without slowing innovation.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20063, Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees
The FDA is looking for smart, qualified people to join its advisory committees and help make important decisions about food and drugs. If you have the right skills, you can apply anytime, but get your nomination in by November 30, 2026, for the best chance at current openings. This is a great chance to influence public health without any cost to you!
Previous / Next Documents
Previous: 2025-10786, Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Fungal Nucleic Acids Directly in Respiratory Specimens
The FDA is officially putting devices that detect fungal DNA in lung samples into a special safety category called Class II. This means these devices will have clear rules to keep them safe and effective, helping patients get better, faster tests. Companies making these devices should get ready for the new rules, which aim to speed up innovation without extra costs or delays.
Next: 2025-10788, Medical Devices; Immunology and Microbiology Devices; Classification of the Clinical Mass Spectrometry Microorganism Identification and Differentiation System
The FDA is officially putting a new type of medical device, called the clinical mass spectrometry microorganism identification and differentiation system, into a special safety category called Class II. This means the device will have clear safety rules to follow, making sure it works well and is safe for patients. This change helps companies bring these cool, innovative tools to doctors faster without extra red tape.